Connecting Industry Assets and Researchers to Drive Neglected Disease R&D
WIPO Re:Search is a global consortium founded by BVGH, the World Intellectual Property Organization (WIPO) and leading pharmaceutical companies. The aim of the Consortium is to accelerate the development of new drugs, vaccines, and diagnostics for neglected tropical diseases (NTDs), malaria, and tuberculosis through the sharing of intellectual property (IP).
Developing New Drugs to Tackle Malaria Resistance
Drug resistance threatens progress in the battle against malaria. To enable discovery of new antimalarials, Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside of the US and Canada) shared aspartyl protease inhibitors with researchers from the Walter and Eliza Hall Institute of Medical Research (WEHI), Australia. With Wellcome Trust Pathfinder Award support, Merck & Co. and the WEHI researchers are developing compounds targeting plasmepsin V, a key parasite enzyme.
Types of Intellectual Property Assets Shared
R&D partnerships established since 2011
Members from 30+ countries
Diseases addressed by the Consortium
Collaborations established in 2017
What do our partners say about WIPO Re:Search?
WIPO Re:Search is an innovative platform that helps companies share their IP assets—including those developed to treat non-communicable diseases—to stimulate NTD product discovery. By connecting industry's assets with disease experts, WIPO Re:Search can accelerate the development of much needed drugs, vaccines, and diagnostics. We are very satisﬁed with BVGH’s partnership coordination services, which help ensure that our IP assets are being put to best use for neglected disease R&D.
The role of industry in improving global health cannot be understated. We have been, and must continue to be, leaders, experts, innovators, and—most importantly—partners in global efforts to reduce suffering and the burden of disease.
Our Sponsor Members
* Known as EMD in the US and Canada
** Known as MSD outside of the US and Canada